A Growing Pipeline of Innovative Drug Candidates for Immune-Mediated Inflammation and Cancer Therapies.
AltruBio has built a differentiated niche pipeline for antibody-targeted therapy with products at various stages of development.
AbGn-168H Neihulizumab
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase II
POC ready and to bridge with s.c. version.
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase II
Inflammatory T Cell Control Antibody for TNF-i and/or Entyvio or JAK-i Refractory Ulcerative Colitis, Phase ll ongoing.
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase I
Inflammatory T Cell Control Antibody for Steroid Refractory-Acute Graft versus Host Disease (GvHD) , Phase 1 ongoing (in patients).
AbGn-268 Leiolizumab
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Preclinical
Potency improved version of AbGn-168H for Chronic Inflammatory Disease
AbGn-107
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Phase I
Antibody Drug Conjugate for Gastrointestinal Cancer, currently in cohort expansion phase of clinical study for efficacy assessment in advanced Gastric Cancer, Pancreatic Cancer, Biliary Cancer and Colorectal Cancer patients
AbGn-207
Preclinical
Phase I
Phase IIa
Phase IIb
Phase lll
Market
Preclinical
CAR-T for Antigen Positive Cancer
Mar, 2020
AltruBio
top